The week in pharma: action, reaction and insight – week to December 1, 2023

By Barbara Obstoj-Cardwell. Editor

Among last week’s interesting research news, US biotech 89bio on Monday released encouraging new data on pegozafermin, its non-alcoholic steatohepatitis (NASH) candidate. Also, pharma major AbbVie reported long-awaited Phase II data for its lung cancer drug Teliso-V (telisotuzumab-vedotin). On the deal-making front, US RNA focused biotech Avidity Biosciences signed a collaboration with Bristol Myers Squibb, which could earn it as much as $2.3 billion. Of note, the US Food and Drug Administration (FDA) last week revealed it has received reports of T-cell malignancies associated with CAR-t cell therapy treatment and has instigated an investigation into the matter. AbbVie returned to the news limelight on Thursday, announcing it has reached agreement to acquire antibody-drug conjugates (ADCs) focused biotech ImmunoGen and its flagship cancer drug Elahere.

Long-term ENLIVEN data show continued benefit and Safety for pegozafermin in NASH